At present, the global innovative drugs mainly come from the top ten pharmaceutical companies with strong strength and some start-up high tech pharmaceutical companies. While there are a large number of generic pharmaceutical companies, especially in China and India, and very few pharmaceutical companies have innovative ability. With the reform of the domestic medical system, under the double blow of consistent evaluation and centralized procurement, some generic pharmaceutical companies have fallen into business difficulties. With the further development of centralized procurement, generic pharmaceutical enterprises will face a more severe business situation, and the concentration ratio of the domestic pharmaceuticals industry will inevitably increase.
The generic pharmaceutical enterprises have been surviving by long-term generic research and development, and do not have the research and development ability of innovative drugs, while the business situation changes instantaneously. Innovative drug research and development takes a long time, costs a lot, and the risks are high, generic pharmaceutical enterprises have neither the ability for innovative drug research and development nor the ability to control the risks of innovative drug research and development.
After conventional drugs are made into microneedle dosage form, they are generally reduced dosage and side effects. When it is difficult to develop a new type of innovative drugs, generic pharmaceutical enterprises choose to combine the conventional drugs and microneedle dosage form, which is a breakthrough direction, and the risk of R&D failure is sharply reduced. Microneedle technology is a high threshold, conventional drugs plus microneedle products enjoy the market treatment of a new type of innovative drugs.
R&D cooperation on generic drugs